Decision-making for PCV in adults

References

• Centers for Disease Control and Prevention. Advisory committee on immunization practices. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep. 2010;59:1102–1106.
   PubMedGoogle Scholar
• Metersky ML, Dransfield MT, Jackson LA. Determining the optimal pneumococcal vaccination strategy for adults: is there a role for the pneumococcal conjugate vaccine? Chest. 2010;138:486–490. doi:10.1378/chest.10-0738.
   PubMed Web of Science ®Google Scholar
• Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2013; (1):CD000422.doi:10.1002/14651858.CD000422.pub3
   PubMed Web of Science ®Google Scholar
• Macleod CM, Hodges RG, Heidelberger M, Bernhard WG. Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. J Exp Med. 1945;82:445–465. doi:10.1084/jem.82.6.445.
   Web of Science ®Google Scholar
• Nichol KL, Baken L, Wuorenma J, Nelson A. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. Arch Intern Med. 1999;159:2437–2442.
   PubMed Web of Science ®Google Scholar
• Simberkoff MS, Cross AP, Al-Ibrahim M, Baltch AL, Geiseler PJ, Nadler J, Richmond AS, Smith RP, Schiffman G, Shepard DS. Efficacy of pneumococcal vaccine in high-risk patients. Results of a veterans administration cooperative study. N Engl J Med. 1986;315:1318–1327. doi:10.1056/NEJM198611203152104.
   PubMed Web of Science ®Google Scholar
• Koivula I, Sten M, Leinonen M, Makela PH. Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial. Am J Med. 1997;103:281–290.
   PubMed Web of Science ®Google Scholar
• Ortqvist A, Hedlund J, Burman LA, Elbel E, Hofer M, Leinonen M, Lindblad I, Sundelöf B, Kalin M. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish pneumococcal vaccination study group. Lancet. 1998;351:399–403.
   PubMed Web of Science ®Google Scholar
• Honkanen PO, Keistinen T, Miettinen L, Herva E, Sankilampi U, Laara E, Leinonen M, Kivelä SL, Mäkelä PH. Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older. Vaccine. 1999;17:2493–2500.
   PubMed Web of Science ®Google Scholar
• Davis AL, Aranda CP, Schiffman G, Christianson LC. Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease. A pilot study. Chest. 1987;92:204–212.
   PubMed Web of Science ®Google Scholar
• Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. Cmaj. 2009;180:48–58. doi:10.1503/cmaj.080734.
   PubMed Web of Science ®Google Scholar
• Dear K, Holden J, Andrews R, Tatham D. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2003; (4):CD000422.
   PubMedGoogle Scholar
• Musher DM, Rueda-Jaimes AM, Graviss EA, Rodriguez-Barradas MC. Effect of pneumococcal vaccination: a comparison of vaccination rates in patients with bacteremic and nonbacteremic pneumococcal pneumonia. Clin Infect Dis. 2006;43:1004–1008. doi:10.1086/507699.
   PubMed Web of Science ®Google Scholar
• Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG,Hadler S, Pilishvili T. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the advisory committee on immunization practices (ACIP). Mmwr. 2014;63:822–825.
   PubMed Web of Science ®Google Scholar
• Vila-Corcoles A, Ochoa-Gondar O, Rodriguez-Blanco T, Raga-Luria X, Gomez-Bertomeu F. Epivac study group. Epidemiology of community-acquired pneumonia in older adults: a population-based study. Respir Med. 2009;103:309–316. doi:10.1016/j.rmed.2008.08.006.
   PubMed Web of Science ®Google Scholar
• Jackson LA, Neuzil KM, Yu O, Benson P, Barlow WE, Adams AL, Hanson CA, Mahoney LD, Shay DK, Thompson WW. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med. 2003;348:1747–1755. doi:10.1056/NEJMoa022678.
   PubMed Web of Science ®Google Scholar
• Latifi-Navid H, Latifi-Navid S, Mostafaiy B, Jamalkandi SA, Ahmadi A. Pneumococcal disease and the effectiveness of the PPV23 vaccine in adults: A two-stage bayesian meta-analysis of observational and RCT reports. Sci Rep. 2018;8:11051. doi:10.1038/s41598-018-29280-2.
   PubMed Web of Science ®Google Scholar
• Schuchat A. Pneumococcal prevention gets older and wiser. JAMA Intern Med. 2015;175:1897–1898. doi:10.1001/jamainternmed.2015.6133.
   PubMed Web of Science ®Google Scholar
• Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, van Werkhoven CH, van Deursen AMM, Sanders EAM, Verheij TJM, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372:1114–1125. doi:10.1056/NEJMoa1408544.
   PubMed Web of Science ®Google Scholar
• Khoie T, Tiernan R, deVore N. FDA briefing document. Prevnar 13 (PCV13): pneumococcal 13-valent conjugate vaccine (Diphtheria CRM197 Protein). Applicant. Silver Spring, Maryland: Wyeth Pharmaceuticals Inc; 2011.
   Google Scholar
• Shiri T, Datta S, Madan J, Tsertsvadze A, Royle P, Keeling MJ, et al. Indirect effects of childhood pneumococcal conjugate vaccination on invasive pneumococcal disease: A systematic review and meta-analysis. Lancet Glob Health. 2017;5:e51–e9.
   Web of Science ®Google Scholar
• Deloria Knoll M, Park DE, Johnson TS, Chandir S, Nonyane BA, Conklin L, Fleming-Dutra KE, Loo JD, Goldblatt D, Whitney CG, et al. Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on immunogenicity. Pediatr Infect Dis J. 2014;33(Suppl 2):S119–29. doi:10.1097/INF.0000000000000079.
   PubMed Web of Science ®Google Scholar
• Whitney CG. Examining duration of protection: should a booster dose be part of all infant pneumococcal conjugate vaccine programs? Clin Infect Dis. 2018;67:375–377. doi:10.1093/cid/ciy135.
   PubMed Web of Science ®Google Scholar
• Said MA, Johnson HL, Nonyane BA, et al. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS One. 2013;8:e60273. doi:10.1371/journal.pone.0060273.
   PubMed Web of Science ®Google Scholar
• Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, Reed C, Grijalva CG, Anderson EJ, Courtney DM, et al. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med. 2015;373:415–427. doi:10.1056/NEJMoa1500245.
   PubMed Web of Science ®Google Scholar
• Marston BJ, Plouffe JF, File TM Jr., Hackman BA, Salstrom SJ, Lipman HB, Kolczak MS, Breiman RF. Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance study in Ohio. The community-based pneumonia incidence study group. Arch Intern Med. 1997;157:1709–1718.
   PubMed Web of Science ®Google Scholar
• Ramirez JA, Wiemken TL, Peyrani P, Arnold FW, Kelley R, Mattingly WA, Nakamatsu R, Pena S, Guinn BE, Furmanek SP, et al. Adults hospitalized with pneumonia in the United States: incidence, epidemiology, and mortality. Clin Infect Dis. 2017;65:1806–1812. doi:10.1093/cid/cix647.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. . Use of13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the advisory committee on immunization practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012;61:816–819.
   PubMedGoogle Scholar
• Shea KM, Edelsberg J, Weycker D, Farkouh RA, Strutton DR, Pelton SI. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis. 2014;1:ofu024. doi:10.1093/ofid/ofu088.
   PubMedGoogle Scholar
• van Aalst M, Lotsch F, Spijker R, van der Meer JTM, Langendam MW, Goorhuis A, Grobusch MP, de Bree GJ. Incidence of invasive pneumococcal disease in immunocompromised patients: A systematic review and meta-analysis. Travel Med Infect Dis. 2018;24:89–100. doi:10.1016/j.tmaid.2018.05.016.
   PubMed Web of Science ®Google Scholar
• Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, Napolitano LM, O’Grady NP, Bartlett JG, Carratalà J, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American thoracic society. Clin Infect Dis. 2016;63:e61–e111. doi:10.1093/cid/ciw353.
   PubMed Web of Science ®Google Scholar
• Jackson ML, Neuzil KM, Thompson WW, Shay DK, Yu O, Hanson CA, Jackson LA. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis. 2004;39:1642–1650. doi:10.1086/425615.
   PubMed Web of Science ®Google Scholar
• Sato R, Gomez Rey G, Nelson S, Pinsky B. Community-acquired pneumonia episode costs by age and risk in commercially insured US adults aged >/=50 years. Appl Health Econ Health Policy. 2013;11:251–258. doi:10.1007/s40258-013-0026-0.
   PubMedGoogle Scholar
• Thomas CP, Ryan M, Chapman JD, Stason WB, Tompkins CP, Suaya JA, Polsky D, Mannino DM, Shepard DS. Incidence and cost of pneumonia in medicare beneficiaries. Chest. 2012;142:973–981. doi:10.1378/chest.11-1160.
   PubMed Web of Science ®Google Scholar
• Yu H, Rubin J, Dunning S, Li S, Sato R. Clinical and economic burden of community-acquired pneumonia in the medicare fee-for-service population. J Am Geriatr Soc. 2012;60:2137–2143. doi:10.1111/j.1532-5415.2012.04208.x.
   PubMed Web of Science ®Google Scholar
• Nelson JC, Jackson M, Yu O, Whitney CG, Bounds L, Bittner R, Zavitkovsky A, Jackson LA. Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults. Vaccine. 2008;26:4947–4954. doi:10.1016/j.vaccine.2008.07.016.
   PubMed Web of Science ®Google Scholar
• Self WH, Courtney DM, McNaughton CD, Wunderink RG, Kline JA. High discordance of chest x-ray and computed tomography for detection of pulmonary opacities in ED patients: implications for diagnosing pneumonia. Am J Emerg Med. 2013;31:401–405. doi:10.1016/j.ajem.2012.08.041.
   PubMed Web of Science ®Google Scholar
• Hayden GE, Wrenn KW. Chest radiograph vs. computed tomography scan in the evaluation for pneumonia. J Emerg Med. 2009;36:266–270. doi:10.1016/j.jemermed.2007.11.042.
   PubMed Web of Science ®Google Scholar
• Esayag Y, Nikitin I, Bar-Ziv J, Cytter R, Hadas-Halpern I, Zalut T, Yinnon AM. Diagnostic value of chest radiographs in bedridden patients suspected of having pneumonia. Am J Med. 2010;123:88 e1–5. doi:10.1016/j.amjmed.2009.09.012.
   Web of Science ®Google Scholar
• Cortellaro F, Colombo S, Coen D, Duca PG. Lung ultrasound is an accurate diagnostic tool for the diagnosis of pneumonia in the emergency department. Emerg Med J. 2012;29:19–23. doi:10.1136/emj.2010.101584.
   PubMed Web of Science ®Google Scholar
• Kea B, Gamarallage R, Vairamuthu H, Fortman J, Lunney K, Hendey GW, Rodriguez RM. What is the clinical significance of chest CT when the chest x-ray result is normal in patients with blunt trauma? Am J Emerg Med. 2013;31:1268–1273. doi:10.1016/j.ajem.2013.04.021.
   PubMed Web of Science ®Google Scholar
• Gessner BD, Jiang Q, Van Werkhoven CH, Sings HL, Webber C, Scott D, Neuzil KM, O’Brien KL, Wunderink RG, Grobbee DE, et al. A public health evaluation of 13-valent pneumococcal conjugate vaccine impact on adult disease outcomes from a randomized clinical trial in the Netherlands. Vaccine. 2018. doi:10.1016/j.vaccine.2018.05.097.
   Google Scholar
• Leeming JP, Cartwright K, Morris R, Martin SA, Smith MD. South-west pneumococcus study G. Diagnosis of invasive pneumococcal infection by serotype-specific urinary antigen detection. J Clin Microbiol. 2005;43:4972–4976. doi:10.1128/JCM.43.10.4972-4976.2005.
   PubMed Web of Science ®Google Scholar
• Smith MD, Derrington P, Evans R, Creek M, Morris R, Dance DA, Cartwright K. Rapid diagnosis of bacteremic pneumococcal infections in adults by using the binax NOW streptococcus pneumoniae urinary antigen test: a prospective, controlled clinical evaluation. J Clin Microbiol. 2003;41:2810–2813.
   PubMed Web of Science ®Google Scholar
• Pride MW, Huijts SM, Wu K, Souza V, Passador S, Tinder C, Song E, Elfassy A, McNeil L, Menton R, et al. Validation of an immunodiagnostic assay for detection of 13 streptococcus pneumoniae serotype-specific polysaccharides in human urine. CVI. 2012;19:1131–1141. doi:10.1128/CVI.00064-12.
   Google Scholar
• Pride MW, Jansen KU. Reevaluation of positivity cutoff values for the pneumococcal urinary antigen detection assay. CVI. 2017;24:e00239–17. (in press). doi:10.1128/CVI.00239-17.
   Google Scholar
• Wunderink RG, Self WH, Anderson EJ, Balk R, Fakhran S, Courtney DM, Qi C, Williams DJ, Zhu Y, Whitney CG, et al. Pneumococcal community-acquired pneumonia detected by serotype-specific urinary antigen detection assays. Clin Infect Dis. 2018. doi:10.1093/cid/cix1066.
   Google Scholar
• Ramirez J, Alexander R, Carrico R, Ford K, Gray S, Pride M, Sebastian S, Jiang Q, Peyrani P, Isturiz R. Distribution of PCV13 pneumococcal serotypes in patients with community-acquired pneumonia presenting at 20 United States hospitals. Open Forum Infect Dis. 2015;2:1582. doi:10.1093/ofid/ofv133.1135.
   Google Scholar
• Alexander RM, Peyrani P, Ramirez J, Self WH, Grijalva CG, Counselman F, Volturo GA, Kabler H, Ostrosky-Zeichner L, Wunderink R, et al. Rationale and methods of the study protocol: streptococcus pneumoniae serotypes in adults 18 years and older with radiographically-confirmed community-acquired pneumonia (CAP). JRI. 2017;1:35–39. doi:10.18297/JRI/.
   Google Scholar
• McLaughlin JM. Presentation at the advisory committee on immunization practices (ACIP): Effectiveness of PCV13 in US adults. Atlanta (GA): Centers for Disease Control and Prevention; 2018 Feb 22.
   Google Scholar
• McLaughlin JM, Jiang Q, Isturiz RE, Sings HL, Swerdlow DL, Gessner BD, Carrico RM, Peyrani P, Wiemken TL, Mattingly WA, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine against hospitalization for community-acquired pneumonia in older US adults: a test-negative design. Clin Infect Dis. 2018 Oct 30;67(10):1498–1506. doi:10.1093/cid/ciy312.
   Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Pneumococcal disease surveillance and reporting. National center for immunization and respiratory diseases division of bacterial diseases; 2018 Feb 16. https://www.cdc.gov/pneumococcal/surveillance.html.
   Google Scholar
• Ladhani SN, Collins S, Djennad A, Sheppard CL, Borrow R, Fry NK, Andrews NJ, Miller E, Ramsay ME. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study. Lancet Infect Dis. 2018;18:441–451. doi:10.1016/S1473-3099(18)30052-5.
   PubMed Web of Science ®Google Scholar
• Musher DM, Rodriguez-Barradas MB. Why the recent ACIP recommendations regarding conjugate pneumococcal vaccine in adults may be irrelevant. Hum Vaccin Immunother. 2016;12:331–335. doi:10.1080/21645515.2015.1098794.
   PubMed Web of Science ®Google Scholar
• Isturiz RE, Hall-Murray C, McLaughlin JM, Snow V, Schmoele-Thoma B, Webber C, Thompson A, Scott DA. Pneumococcal conjugate vaccine use for the prevention of pneumococcal disease in adults < 50 years of age. Expert Rev Vaccines. 2018;17:45–55. doi:10.1080/14760584.2018.1411196.
   PubMed Web of Science ®Google Scholar
• Black CL, Williams WW, Warnock R, Pilishvili T, Kim D, Kelman JA. Pneumococcal vaccination among medicare beneficiaries occurring after the advisory committee on immunization practices recommendation for routine use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults aged ≥ 65 years. MMWR Morb Mortal Wkly Rep. 2017;66:728–733. doi:10.15585/mmwr.mm6627a4.
   PubMed Web of Science ®Google Scholar
• Pfizer data on file provided by IQVIA. Durham, NC.
   Google Scholar
• McLaughlin JM, Khan F, Curry A, Snow V, Isturiz RE, Swerdlow DL. Disparities in uptake of 13-valent pneumococcal conjugate vaccine among older adults following routine recommendation in the United States. Open Forum Infect Dis. 2017 Fall;2017:S468–S9. doi:10.1093/ofid/ofx163.1197.
   Google Scholar
• McLaughlin JM, Swerdlow DL, Isturiz RE, Jodar L. Rethinking number-needed-to-vaccinate for pneumococcal conjugate vaccines in older adults: current and future implications. Vaccine. 2017;35:5360–5365. doi:10.1016/j.vaccine.2017.08.028.
   PubMed Web of Science ®Google Scholar
• Patterson S, Webber C, Patton M, Drews W, Huijts SM, Bolkenbaas M, Gruber WC, Scott DA, Bonten MJM. A post hoc assessment of duration of protection in CAPiTA (community acquired pneumonia immunization trial in adults). Trials Vaccinol. 2016;5:92–96. doi:10.1016/j.trivac.2016.04.004.
   Google Scholar
• Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 1997;46:1–24.
   PubMedGoogle Scholar
• Weycker D, Strutton D, Edelsberg J, Sato R, Jackson LA. Clinical and economic burden of pneumococcal disease in older US adults. Vaccine. 2010;28:4955–4960. doi:10.1016/j.vaccine.2010.05.030.
   PubMed Web of Science ®Google Scholar
• Pfizer data on file. Collegeville, PA.
   Google Scholar
• Dagan R, Patterson S, Juergens C, Greenberg D, Givon-Lavi N, Porat N, Gurtman A, Gruber WC, Scott DA. Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial. Clin Infect Dis. 2013;57:952–962. doi:10.1093/cid/cit428.
   PubMed Web of Science ®Google Scholar
• Sings HL, De Wals P, Gessner BD, Isturiz R, Laferriere C, McLaughlin JM, Pelton S, Schmitt HJ, Suaya J.A, Jodar L. Effectiveness of 13-valent pneumococcal conjugate vaccine against invasive disease caused by serotype 3 in children: a systematic review and meta-analysis of observational studies. Clin Infect Dis. 2018. doi: 10.1093/cid/ciy920
   Google Scholar
• Perniciaro S, Van Der Linden M, Imöhl M. Reduced effect of the pediatric pneumococcal conjugate vaccination on invasive pneumococcal disease in adults in Germany. 28th ECCMID, Madrid, Spain. 2018;P0586.
   Google Scholar
• Burton DC, Flannery B, Bennett NM, Farley MM, Gershman K, Harrison LH, Lynfield R, Petit S, Reingold AL, Schaffner W, et al. Socioeconomic and racial/ethnic disparities in the incidence of bacteremic pneumonia among US adults. Am J Public Health. 2010;100:1904–1911. doi:10.2105/AJPH.2009.181313.
   PubMed Web of Science ®Google Scholar
• Kyaw MH, Rose CE Jr., Fry AM, Singleton JA, Moore Z, Zell ER, Whitney CG. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis. 2005;192:377–386. doi:10.1086/431521.
   PubMed Web of Science ®Google Scholar
• Soto K, Petit S, Hadler JL. Changing disparities in invasive pneumococcal disease by socioeconomic status and race/ethnicity in Connecticut, 1998-2008. Public Health Rep. 2011;126(Suppl 3):81–88. doi:10.1177/00333549111260S313.
   PubMedGoogle Scholar
• McLaughlin JM, Utt EA, Hill NM, Welch VL, Power E, Sylvester GC. A current and historical perspective on disparities in US childhood pneumococcal conjugate vaccine adherence and in rates of invasive pneumococcal disease: considerations for the routinely-recommended, pediatric PCV dosing schedule in the United States. Hum Vaccin Immunother. 2016;12:206–212. doi:10.1080/21645515.2015.1069452.
   PubMed Web of Science ®Google Scholar
• Warren JL, Pingali SC, Weinberger DM. Spatial variability in the persistence of pneumococcal conjugate vaccine-targeted pneumococcal serotypes among adults. Epidemiology. 2017;28:119–126. doi:10.1097/EDE.0000000000000551.
   PubMed Web of Science ®Google Scholar
• Dube E, Gagnon D, Nickels E, Jeram S, Schuster M. Mapping vaccine hesitancy–country-specific characteristics of a global phenomenon. Vaccine. 2014;32:6649–6654. doi:10.1016/j.vaccine.2014.09.039.
   PubMed Web of Science ®Google Scholar
• Dube E, Vivion M, MacDonald NE. Vaccine hesitancy, vaccine refusal and the anti-vaccine movement: influence, impact and implications. Expert Rev Vaccines. 2015;14:99–117. doi:10.1586/14760584.2015.964212.
   PubMed Web of Science ®Google Scholar
• Larson HJ, Jarrett C, Eckersberger E, Smith DM, Paterson P. Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: a systematic review of published literature, 2007-2012. Vaccine. 2014;32:2150–2159. doi:10.1016/j.vaccine.2014.01.081.
   PubMed Web of Science ®Google Scholar
• Siddiqui M, Salmon DA, Omer SB. Epidemiology of vaccine hesitancy in the United States. Hum Vaccin Immunother. 2013;9:2643–2648. doi:10.4161/hv.27243.
   PubMed Web of Science ®Google Scholar
• Chatterjee A, O’Keefe C. Current controversies in the USA regarding vaccine safety. Expert Rev Vaccines. 2010;9:497–502. doi:10.1586/erv.10.36.
   PubMed Web of Science ®Google Scholar
• Williams WW, Lu PJ, O’Halloran A, Kim DK, Grohskopf LA, Pilishvili T, Skoff TH, Nelson NP, Harpaz R, Markowitz LE, et al. Surveillance of vaccination coverage among adult populations - United States, 2015. MMWR Surveill Summ. 2017;66:1–28. doi:10.15585/mmwr.ss6611a1.
   PubMed Web of Science ®Google Scholar